Phase 3 trial, 231 patients with locally advanced rectal cancer: short-course radiotherapy, camrelizumab and CAPOX vs long-course chemoradiotherapy then CAPOX. Primary pCR 39.8% vs 15.3%; interim 3-year event-free survival 91.3% vs 77.4% (HR 0.33).
RCTn = 231
Tao et al. Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial